COSCIENS Biopharma (CSCI) 6-K 13 Aug 19 2019 Q2 Condensed Interim Consolidated Financial Statements Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2019
Cover [Abstract]
Entity Registrant Name	Aeterna Zentaris Inc.
Entity Central Index Key	0001113423
Document Type	6-K
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 9,683	$ 14,512
Trade and other receivables (note 6)	494	294
Inventory	562	240
Prepaid expenses and other current assets	1,030	1,210
Total current assets	11,769	16,256
Restricted cash	367	418
Right of use assets (note 4)	340
Property, plant and equipment	48	65
Identifiable intangible assets	50	62
Goodwill	8,177	8,210
Total assets	20,751	25,011
Current liabilities
Payables and accrued liabilities (note 7)	3,200	2,966
Provision for restructuring and other costs (note 8)	1,004	887
Income taxes payable	1,662	1,669
Current portion of deferred revenues	74	74
Current portion of lease liabilities (note 4)	635
Current portion of warrant liability (note 9)	447
Total current liabilities	7,022	5,596
Deferred revenues	222	258
Lease liabilities (note 4)	570
Warrant liability (note 9)	1,004	3,634
Employee future benefits (note 10)	14,561	13,205
Non-current portion of provision for restructuring and other costs (note 8)	400	411
Total liabilities	23,779	23,104
SHAREHOLDERS' (DEFICIENCY) EQUITY
Share capital	223,140	222,335
Other capital	89,824	89,342
Deficit	(315,977)	(309,781)
Accumulated other comprehensive (loss) income	(15)	11
Total shareholders' (deficiency) equity	(3,028)	1,907
Total liabilities and shareholders' (deficiency) equity	$ 20,751	$ 25,011

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Changes in Shareholders' (Deficiency) Equity (Unaudited) - USD ($) $ in Thousands	Share Capital [Member]	Other Capital [Member]	Deficit [Member]	Accumulated Other Comprehensive (loss) Income [Member]	Total
Balance at Dec. 31, 2017	$ 222,335	$ 88,772	$ (314,161)	$ 271	$ (2,783)
Balance, shares at Dec. 31, 2017	16,440,760
Net income (loss)			11,822		11,822
Other comprehensive loss: Foreign currency translation adjustments				(250)	(250)
Other comprehensive loss: Actuarial loss on defined benefit plan (note 10)			205		205
Comprehensive income (loss)			12,027	(250)	11,777
Share-based compensation costs		516			516
Balance at Jun. 30, 2018	$ 222,335	89,288	(302,134)	21	9,510
Balance, shares at Jun. 30, 2018	16,440,760
Balance at Mar. 31, 2018	$ 222,335	88,895	(299,737)	49	11,542
Balance, shares at Mar. 31, 2018	16,440,760
Net income (loss)			(2,602)		(2,602)
Other comprehensive loss: Foreign currency translation adjustments				(28)	(28)
Other comprehensive loss: Actuarial loss on defined benefit plan (note 10)			205		205
Comprehensive income (loss)			(2,397)	(28)	(2,425)
Share-based compensation costs		393			393
Balance at Jun. 30, 2018	$ 222,335	89,288	(302,134)	21	9,510
Balance, shares at Jun. 30, 2018	16,440,760
Balance at Dec. 31, 2018	$ 222,335	89,342	(309,781)	11	1,907
Balance, shares at Dec. 31, 2018	16,440,760
Net income (loss)			(4,705)		(4,705)
Other comprehensive loss: Foreign currency translation adjustments				(26)	(26)
Other comprehensive loss: Actuarial loss on defined benefit plan (note 10)			(1,491)		(1,491)
Comprehensive income (loss)			(6,196)	(26)	(6,222)
Issuance of common shares	$ 805				805
Issuance of common shares, shares	191,650
Share-based compensation costs		482			482
Balance at Jun. 30, 2019	$ 223,140	89,824	(315,977)	(15)	(3,028)
Balance, shares at Jun. 30, 2019	16,632,410
Balance at Mar. 31, 2019	$ 222,335	89,437	(315,427)	95	(3,560)
Balance, shares at Mar. 31, 2019	16,440,760
Net income (loss)			206		206
Other comprehensive loss: Foreign currency translation adjustments				(110)	(110)
Other comprehensive loss: Actuarial loss on defined benefit plan (note 10)			(756)		(756)
Comprehensive income (loss)			(550)	(110)	(660)
Issuance of common shares	$ 805				805
Issuance of common shares, shares	191,650
Share-based compensation costs		387			387
Balance at Jun. 30, 2019	$ 223,140	$ 89,824	$ (315,977)	$ (15)	$ (3,028)
Balance, shares at Jun. 30, 2019	16,632,410

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues
Royalty income (note 5)	$ 8		$ 21
Product sales (note 5)	129		129
Sales commission and other	39	79	45	169
Licensing revenue (note 5)	18	89	36	24,657
Total revenues	194	168	231	24,826
Cost of goods sold	101	197	101	197
Gross income (loss)	93	(29)	130	24,629
Research and development costs	571	974	1,099	1,807
General and administrative expenses	1,923	2,004	3,560	4,790
Selling expenses	495	497	799	2,138
Restructuring costs (note 8)	773		773
Impairment of right of use asset (note 4)	64		401
Write-off of other current assets			169
Total operating expenses	3,826	3,475	6,801	8,735
(Loss) income from operations	(3,733)	(3,504)	(6,671)	15,894
(Loss) gain due to changes in foreign currency exchange rates	(6)	677	58	725
Change in fair value of warrant liability (note 9)	3,926	(134)	1,865	1,694
Other finance income	19	126	43	144
Net finance income	3,939	669	1,966	2,563
Income (loss) before income taxes	206	(2,835)	(4,705)	18,457
Income tax recovery (expense)		233		(6,635)
Net income (loss)	206	(2,602)	(4,705)	11,822
Items that may be reclassified subsequently to profit or loss:
Foreign currency translation adjustments	(110)	(28)	(26)	(250)
Items that will not be reclassified to profit or loss:
Actuarial loss (gain) on defined benefit plans	(756)	205	(1,491)	205
Comprehensive (loss) income	$ (660)	$ (2,425)	$ (6,222)	$ 11,777
Net (loss) income per share [basic]	$ 0.01	$ (0.16)	$ (0.28)	$ 0.72
Net (loss) income per share [diluted]	$ 0.01	$ (0.16)	$ (0.28)	$ 0.70
Weighted average number of shares outstanding (note 17):
Basic	16,622,415	16,440,760	16,532,090	16,440,760
Diluted	17,260,016	16,440,760	16,532,090	16,489,364

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net income (loss) for the period	$ 206	$ (2,602)	$ (4,705)	$ 11,822
Items not affecting cash and cash equivalents:
Change in fair value of warrant liability (note 9)	(3,926)	134	(1,865)	(1,694)
Provision for restructuring costs (note 8)	790		773	(214)
Depreciation and amortization	70	21	136	35
Impairment of right of use asset (note 4)	64		401
Write-off of current assets			169
Deferred income taxes				3,479
Share-based compensation costs	595	392	690	515
Employee future benefits (note 10)	2	(311)	136	(233)
Amortization of deferred revenues	(18)		(36)	(541)
Foreign exchange loss on items denominated in foreign currencies	(4)	(629)	(49)	(729)
Gain on disposal of property, plant and equipment			(3)	9
Other non-cash items		8		24
Changes in operating assets and liabilities (note 13)	51	(1,790)	(823)	(533)
Net cash (used in) provided by operating activities	(2,170)	(4,777)	(5,176)	11,940
Cash flows from financing activities
Proceeds from issuance of common shares	314		314
Payments on lease liability	(159)		(310)
Net cash from financing activities	155		4
Cash flows from investing activities
Disposal of property, plant and equipment				11
Change in restricted cash			50
Net cash from investing activities			50	11
Effect of exchange rate changes on cash and cash equivalents	341	175	293	215
Net change in cash and cash equivalents	(1,674)	(4,602)	(4,829)	12,166
Cash and cash equivalents - Beginning of period	11,357	24,548	14,512	7,780
Cash and cash equivalents - End of period	$ 9,683	$ 19,946	$ 9,683	$ 19,946

Going Concern

Going Concern	6 Months Ended
	Jun. 30, 2019
Going Concern
Going Concern	1 Going Concern The Company has incurred significant expenses in its efforts to develop and co-promote products. Consequently, the Company has incurred operating losses and negative cash flow from operations historically and in each of the last several years except for the year ended December 31, 2018 when the Company earned revenue from the sale of a license for the adult indication of Macrilen™ (macimorelin) in the United States and Canada (note 5). As at June 30, 2019, the Company had an accumulated deficit of $316 million. The Company also had a net loss of $4,705 for the six months ended June 30, 2019, and negative cash flow from operations of $5,176. The Company’s principal focus is on the licensing and development of Macrilen™ (macimorelin) and it currently does not have any other approved products. Under the terms of License and Assignment Agreement, Novo is funding 70% of the pediatric clinical trial submitted to the EMA and FDA, the Company’s sole development activity. On March 12, 2019, the Company announced that its board of directors formed a special committee of independent directors (the “Special Committee”) to review strategic options available to the Company. The Special Committee has approved the engagement by the Company of a financial advisor that is working with management to assist the Special Committee and the board of directors in considering a wide range of transactions (including opportunities for the license of Macrilen™ (macimorelin) outside of the United States and Canada, or other monetization transactions relating to Macrilen™ (macimorelin). Management has evaluated whether material uncertainties exist relating to events or conditions and has considered the following in making that critical judgment. The ability of the Company to realize its assets and meet its obligations as they come due is dependent on earning sufficient revenues under the License and Assignment Agreement, developing opportunities for Macrilen™ (macimorelin) in the rest of the world, realizing other monetizing transactions, and raising additional sources of funding, the outcome of which cannot be predicted at this time. The revenue provided under the License and Assignment Agreement was $21 for the six months ended June 30, 2019 and as at June 30, 2019, the Company had cash of $9,683. Furthermore, nearly all of the Company’s cash is held in AEZS Germany, our wholly owned German subsidiary. AEZS Germany is also the counter-party for any and all cash received from revenue earned under the License and Assignment Agreement. At the present time, the Company’s North American operations are financed through the repayment of intercompany liabilities by AEZS Germany to the Canadian parent company and its U.S. subsidiary. However, if and when current and medium term liabilities of AEZS Germany exceed the values ascribed to AEZS Germany’s assets, it may no longer be possible under applicable German solvency laws for such cash transfers to take place. Although the Company currently expects AEZS Germany to continue to transfer cash to the Company’s North American operations to finance operations in the Canadian parent company and its U.S. subsidiary, in an amount sufficient for the Company (absent other funding sources) to finance most of its North American obligations, through at least the remainder of 2019, there is significant risk that AEZS Germany’s ability to make these transfers will become restricted. The Company expects to have secured additional financing prior to the end of 2019 from third party sources; however, there is no certainty that the Company will be successful in raising additional sources of cash. The Company has some discretion to manage research and development costs, administrative expenses and capital expenditures in order to maintain its cash liquidity, however the Company will need to obtain equity or debt financing in 2019 in order to fund its ongoing operations. The outcome of these efforts is uncertain. Management has assessed the Company’s ability to continue as a going concern and concluded that additional capital will be required. There can be no assurance that the Company will be able to obtain equity or debt financing, or on terms acceptable to it. Factors within and outside the Company’s control could have a significant bearing on its ability to obtain additional financing. As a result, management has determined that there are material uncertainties that may cast significant doubt upon the Company’s ability to continue as a going concern. These financial statements have been prepared on a going concern basis, which asserts the Company has the ability in the near term to continue to realize its assets and discharge its liabilities and commitments in a planned manner giving consideration to the above and expected possible outcomes. Conversely, if the going concern assumption is not appropriate, adjustments to the carrying amounts of the Company’s assets, liabilities, revenues, expenses and balance sheet classifications may be necessary, and these adjustments could be material.

Summary of Business and Basis o

Summary of Business and Basis of Preparation	6 Months Ended
	Jun. 30, 2019
Summary Of Business And Basis Of Preparation
Summary of Business and Basis of Preparation	2 Summary of business and basis of preparation Summary of business Aeterna Zentaris Inc. (“Aeterna Zentaris” or the “Company”) is a specialty biopharmaceutical company which is commercializing novel pharmaceutical therapies. On December 20, 2017, the United States Food and Drug Administration (“FDA”) granted marketing approval for Macrilen™ (macimorelin) to be used in the diagnosis of patients with adult growth hormone deficiency (“AGHD”). On January 16, 2018, the Company, through Aeterna Zentaris GmbH (“AEZS Germany”), entered into a license and assignment agreement with Strongbridge Ireland Limited (“Strongbridge”) to carry out development, manufacturing, registration, regulatory and supply chain services for the commercialization of Macrilen™ (macimorelin) in the United States and Canada (the “License and Assignment Agreement”). Effective December 19, 2018, Strongbridge sold the United States and Canadian rights to Macrilen™ (macimorelin) under the License and Assignment Agreement to Novo Nordisk A/S (“Novo”). Basis of presentation These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting The accounting policies in these condensed interim consolidated financial statements are consistent with those presented in the Company’s annual consolidated financial statements, except for the adoption, of IFRS 16, Leases, These unaudited condensed interim consolidated financial statements were approved by the Company’s Board of Directors on August 12, 2019 These unaudited condensed interim consolidated financial statements were prepared on a going concern basis.

Critical Accounting Estimates a

Critical Accounting Estimates and Judgments	6 Months Ended
	Jun. 30, 2019
Critical Accounting Estimates And Judgments
Critical Accounting Estimates and Judgments	3 Critical accounting estimates and judgments The preparation of condensed interim consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of the Company’s assets, liabilities, revenues, expenses and related disclosures. Judgments, estimates and assumptions are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s condensed interim consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the condensed interim consolidated financial statements are presented fairly and in accordance with IFRS. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Critical accounting estimates and assumptions, as well as critical judgments used in applying accounting policies in the preparation of the Company’s condensed interim consolidated financial statements, were the same as those found in note 4 to the Company’s annual consolidated financial statements as of December 31, 2018 and 2017 and for the years ended December 31, 2018, and 2017 except for those related to the adoption of IFRS 16, as follows: Critical judgments in determining the lease term and discount rate In determining the lease term, management considers all facts and circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension options (or periods after termination options) are only included in the lease term if the lease is reasonably certain to be extended (or not terminated). In determining the appropriate discount rate, management identified the rate for the building based on the type and location of the Company’s office, laboratory and storage facility in Frankfurt and, for vehicle and equipment leases, used the risk-free rate, credit spread and lease specific adjustment for similar assets.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2019
Disclosure of initial application of standards or interpretations [abstract]
Recent Accounting Pronouncements	4 Recent accounting pronouncements Impact of adoption significant new IFRS standards in 2019 The following new IFRS standards have been adopted by the Company effective January 1, 2019: A) IFRS 16, Leases The Company has adopted IFRS 16 on a modified retrospective basis from January 1, 2019 with no restatement of comparatives, as permitted under the specific transitional provisions in the standard. (i) Adjustments recognized on adoption of IFRS 16 Lease liabilities The Company has operating leases for building, cars and equipment leases at its location in Frankfurt. Upon adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under the principles of IAS 17 Leases. Under IFRS 16, these liabilities were measured at the present value of the remaining lease payments excluding renewal options as they are not expected to be exercised, discounted using the Company’s incremental borrowing rate as of January 1, 2019. The Company’s incremental annual borrowing rate applied to the lease liabilities on January 1, 2019 were: ● Building lease 5.5% ● Car leases ranging from 4.84% to 5.32% ● Equipment leases 3.88% The weighted average incremental borrowing rate applied to lease liabilities recognized in the statement of financial position at January 1, 2019 was 5.45%. 2019 Operating lease commitments disclosed as at December 31, 2018 1,620 Discounted using the lessee’s incremental borrowing rate of at the date of initial application: Lease liability recognized as at January 1, 2019 1,522 Current lease liabilities 629 Non-current lease liabilities 893 During the six-month period ended June 30, 2019 Cash lease payments made 348 Interest paid as charged to comprehensive profit and loss as other finance income 38 Payment against lease liabilities 310 Foreign exchange 7 Lease liability recognized as at June 30, 2019 1,205 Current lease liabilities 635 Non-current lease liabilities 570 The Company’s lease liabilities come due, as at June 30, 2019, as follows: $ Less than 1 year 635 1 - 3 years 560 4 - 5 years 10 More than 5 years — Total 1,205 Right of use assets The Company’s related right of use assets were measured at the amount equal to the lease liability at the date of initial application. Only the building right of use asset was further adjusted by the application of $663 in related onerous lease provision to the value at inception. Building Cars and equipment Total $ $ $ Cost At January 1, 2019 735 124 859 Additions — 26 26 Disposals — (25 ) (25 ) Impact of foreign exchange rate changes (4 ) (5 ) (9 ) At June 30, 2019 731 120 851 Building Cars and equipment Total $ $ $ Accumulated Amortization At January 1, 2019 — — — Disposals — (3 ) (3 ) Amortization 87 30 117 Impairment 401 — 401 Impact of foreign exchange rate changes (2 ) (2 ) (4 ) At June 30, 2019 486 25 511 Building Cars and equipment Total $ $ $ Carrying amount At June 30, 2019 245 95 340 During the three-month period ended March 31, 2019, management continued its search for a sub-lessee. However, there have been delays which led to a reassessment of its onerous lease provision as the Company has determined that its plan to exit its building lease, in full, as at December 31, 2019 was not probable. As such, the Company recognized an impairment of its right of use building asset of $337 in the statement of comprehensive income and loss. In light of the June 2019 restructuring of the German operations (note 8), management recognized an additional impairment of $64 as office and lab space will become vacant or underutilized. Overall impact from adoption The change in accounting policy affected the following items in the balance sheet on January 1, 2019: ● Right of use assets - increase by $859 ● Onerous lease contracts - decrease by $663 ● Lease liabilities - increase by $1,522 Income (loss) per share for the three and six months to June 30, 2019 was not affected as a result of the adoption of IFRS 16. (ii) Practical expedients applied In applying IFRS 16 for the first time, the Company has used the following practical expedients permitted by the standard: ● the use of a single discount rate to a portfolio of leases with reasonably similar characteristics ● reliance on previous assessments on whether leases are onerous ● the exclusion of initial direct costs for the measurement of the right of use asset at the date of initial application; and ● the use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease. The Company has also elected not to reassess whether a contract is or contains a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4 Determining whether an Arrangement contains a Lease. (iii) The Company’s leasing activities and how these are accounted for The Company leases various office and lab premises (building), cars and equipment. The building lease was originally for 10 years with one five-year extension, such extension is ending on April 30, 2021. Car lease contracts are typically made for fixed periods of three to four years while the equipment lease is for five years ending April 30, 2020. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. and the lease agreements do not impose any covenants, but leased assets may not be used as security for borrowing purposes. Until the 2018 financial year, leases of property, plant and equipment were classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) were charged to profit or loss on a straight-line basis over the period of the lease. From January 1, 2019, leases are recognized as a right of use asset and a corresponding liability at the date at which the leased asset is available for use by the Company. Each lease payment is allocated between the liability and finance cost. The finance cost is charged to comprehensive profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right of use assets are measured at cost and are depreciated over the shorter of the assets’ useful life and the lease terms on a straight-line basis, less any accumulated impairment losses and adjusted for any remeasurement of the lease liability. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of its fixed payments (including in-substance fixed payments), less any lease incentives receivable The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee’s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions. Right of use assets are measured at cost comprising the following: ● the amount of the initial measurement of lease liability; ● any lease payments made at or before the commencement date less any lease incentives received; ● any initial direct costs; ● onerous lease provisions as previously determined (note 8); and ● any restoration costs. Payments associated with short-term leases and leases of low-value assets are recognized on a straight-line basis as an expense in the statement of comprehensive profit or loss. B) IFRIC 23, “ Uncertainty over Income Tax Treatment In June 2017, IFRIC 23, was issued and it provides guidance on how to value uncertain income tax positions based on the probability of whether the relevant tax authorities will accept the company’s tax treatments. A company is to assume that a taxation authority with the right to examine any amounts reported to it will examine those amounts and will have full knowledge of all relevant information when doing so. IFRIC 23 is effective for annual periods beginning on or after January 1, 2019. The adoption of this interpretation did not have a significant impact on the Company’s condensed interim consolidated financial statements. C) Amendments in Plan Amendment, Curtailment or Settlement (Amendments to IAS 19) In June 2015, the IASB published ED/2015/5 Remeasurement on a Plan Amendment, Curtailment or Settlement/Availability of a Refund from a Defined Benefit Plan (Proposed amendments to IAS 19 and IFRIC 14) Employee Benefits IAS 19 - The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction Plan Amendment, Curtailment or Settlement (Amendments to IAS 19)

Licensing Arrangement

Licensing Arrangement	6 Months Ended
	Jun. 30, 2019
Subclassifications of assets, liabilities and equities [abstract]
Licensing Arrangement	5 Licensing arrangement On January 16, 2018, the Company, through AEZS Germany, entered into the License and Assignment Agreement with Strongbridge to carry out development, manufacturing, registration, regulatory and supply chain services for the commercialization of Macrilen™ (macimorelin) in the United States and Canada, which provides for (i) the “right to use” license relating to the Adult Indication; (ii) the sale of the right to acquire a license of a future FDA-approved Pediatric Indication; (iii) the agreement by Strongbridge to fund 70% of the costs of a pediatric clinical trial submitted for approval to the EMA and FDA to be run by the Company with customary oversight from a joint steering committee; and (iv) an Interim Supply Arrangement. Effective December 19, 2018, Strongbridge sold the entity which is the licensee under the License and Assignment Agreement to Novo. Royalty income earned under the License and Assignment Agreement for the six-month period ending June 30, 2019 was $21 (2018- $nil). During the six-month period ended June 30, 2019, the Company invoiced Novo $621 for its share of PIP study costs and $839 for supply chain costs.

Trade and Other Receivables

Trade and Other Receivables	6 Months Ended
	Jun. 30, 2019
Trade and other receivables [abstract]
Trade and Other Receivables	6 Trade and other receivables June 30, 2019 December 31, 2018 $ $ Trade accounts receivable (net of allowance for doubtful accounts of $55 (December 31, 2018 - $55) 217 142 Value added tax 247 49 Other 30 103 494 294

Payables and Accrued Liabilitie

Payables and Accrued Liabilities	6 Months Ended
	Jun. 30, 2019
Subclassifications of assets, liabilities and equities [abstract]
Payables and Accrued Liabilities	7 Payables and accrued liabilities June 30, 2019 December 31, 2018 $ $ Trade accounts payable 1,197 1,282 Accrued research and development costs — 26 Salaries, employment taxes and benefits 258 183 Financing of insurance premiums (a) 210 738 Other accrued liabilities 1,535 737 3,200 2,966 (a) Represents financing of the Company’s 2019 insurance premiums, carrying interest at 6.5% and repayable in eight equal monthly installments commencing January 31, 2019.

Provision for Restructuring Cos

Provision for Restructuring Costs	6 Months Ended
	Jun. 30, 2019
Subclassifications of assets, liabilities and equities [abstract]
Provision for Restructuring Costs	8 Provision for restructuring costs In the third quarter of 2017, AEZS Germany, and its Works Council approved a restructuring program (the “2017 German Restructuring”), which was rolled out as a part of the continued strategy to transition into a commercially operating specialty biopharmaceutical organization focused on the commercialization of Macrilen™ (macimorelin). On June 6, 2019, the Company announced that it was further reducing the size of its German workforce to more closely reflect the Company’s ongoing commercial activities in Frankfurt. AEZS Germany and its Works Council approved a restructuring that affects 8 employees and resulted in $773 of severance costs that is expected to be paid by January 31, 2020. The changes in the Company’s provision for restructuring and other costs can be summarized as follows: Cetrotide(R) onerous contracts German Restructuring: onerous lease German Restructuring: severance Total $ $ $ $ Balance – January 1, 2019 547 663 88 1,298 Adoption of IFRS 16 (note 4) — (663 ) — (663 ) Utilization of provision (59 ) — — (59 ) Change in provision 59 — 773 832 Impact of foreign exchange rate changes (2 ) — (2 ) (4 ) Balance – June 30, 2019 545 — 859 1,404 Less current portion (145 ) — (859 ) (1,004 ) Non-current portion 400 — — 400

Warrant Liability

Warrant Liability	6 Months Ended
	Jun. 30, 2019
Warrant Liability
Warrant Liability	9 Warrant liability The change in the Company’s warrant liability can be summarized as follows: Six months ended June 30, 2019 $ Balance – January 1, 2019 3,634 Exercise of warrants (318 ) Change in fair value of warrant liability (1,865 ) Balance – June 30, 2019 1,451 Current portion of warrant liability 447 Long-term portion of warrant liability 1,004 A summary of the activity related to the Company’s share purchase warrants that are classified as a liability is provided below. Six months ended June 30, 2019 Year ended December 31, 2018 Number Weighted average exercise price Number Weighted average exercise price $ $ Balance – Beginning of period 3,391,844 6.23 3,417,840 7.59 Exercised (87,700 ) 1.07 — — Expired — — (25,996 ) 185.00 Balance – End of period 3,304,144 6.36 3,391,844 6.23 The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of all warrants outstanding as at June 30, 2019. The Black-Scholes option pricing model uses “Level 2” inputs, as defined by IFRS 13, Fair value measurement Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (a) (b) (c) (d) March 2015 Series A Warrants (e) 28,144 2.95 1.07 1.91 % 100.09 % 0.70 0.00 % December 2015 Warrants 2,331,000 2.95 7.10 1.83 % 80.62 % 1.46 0.00 % November 2016 Warrants (f) 945,000 2.95 4.70 1.91 % 92.73 % 0.84 0.00 % (a) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations. (c) Based upon time to expiry from the reporting period date. (d) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (e) For the March 2015 Series A Warrants, the inputs and assumptions applied to the Black-Scholes option pricing model have been further adjusted to take into consideration the value attributed to certain anti-dilution provisions. Specifically, the weighted average exercise price is subject to adjustment (see note 11 - Share and other capital). (f) For the November 2016 Warrants, the Company reduced the fair value of these warrants to take into consideration the fair value of the $10.00 call option, which was also calculated using the Black-Scholes pricing model.

Employee Future Benefits

Employee Future Benefits	6 Months Ended
	Jun. 30, 2019
Employee Future Benefits
Employee Future Benefits	10 Employee future benefits The Company sponsors a pension plan in Germany (The Aeterna Zentaris GmbH Pension Plan). The change in the Company’s accrued benefit obligations is summarized as follows: Six months ended June 30, 2019 Year ended December 31, 2018 Pension benefit plans Other benefit plans Total Total $ $ $ $ Balances – Beginning of the period 13,100 105 13,205 14,229 Current service cost 21 3 24 72 Interest cost 111 1 112 225 Actuarial loss (gain) arising from changes in financial assumptions 1,491 — 1,491 (174 ) Benefits paid (217 ) — (217 ) (494 ) Impact of foreign exchange rate changes (53 ) (1 ) (54 ) (653 ) Balances – End of the period 14,453 108 14,561 13,205 Amounts recognized: In net loss (132 ) (4 ) (136 ) (316 ) In other comprehensive loss 1,491 — 1,491 846 The calculation of the pension benefit obligation is sensitive to the discount rate assumption. For the first quarter of 2019, management determined that the discount rate assumption should be adjusted from 1.9% to 1.4% and, for the second quarter of 2019, this was adjusted from 1.4% to 1.1%.

Share and Other Capital

Share and Other Capital	6 Months Ended
	Jun. 30, 2019
Share And Other Capital
Share and Other Capital	11 Share and other capital The Company has an unlimited number of authorized common shares (being voting and participating shares) with no par value, as well as an unlimited number of preferred, first and second ranking shares, issuable in series, with rights and privileges specific to each class, with no par value. Shareholder rights plan Effective May 8, 2019, the shareholders re-approved the Company’s shareholder rights plan (the “Rights Plan”) that provides the board of directors and the Company’s shareholders with additional time to assess any unsolicited take-over bid for the Company and, where appropriate, to pursue other alternatives for maximizing shareholder value. Under the Rights Plan, one right has been issued for each currently issued common share, and one right will be issued with each additional common share that may be issued from time to time. Other capital The Company accounts for costs associated with share-based compensation from security grants under its long-term incentive plan and stock option plans as other capital in its consolidated statements of changes in shareholders’ equity (deficiency) and as general and administrative expenses in its consolidated statements of comprehensive income (loss). Long-term incentive plan During 2019, the Company has only granted Deferred Share Units (DSU) to the members of the board of directors. The following tables summarizes the activity under the LTIP and the Stock Option Plan: Six months ended Year ended June 30, 2019 December 31, 2018 US dollar-denominated stock options and DSU Number Weighted average exercise price Number Weighted average exercise price Balance – Beginning of the period 888,816 3.66 712,415 4.66 Granted 150,000 3.15 426,000 1.74 Exercised (110,850 ) 2.35 — — Forfeited — — (249,599 ) 3.23 Balance – End of period 927,966 3.76 888,816 3.66 Six months ended Year ended June 30, 2019 December 31, 2018 Canadian dollar-denominated options Number Weighted average exercise price Number Weighted average exercise price Balance – Beginning of the period 869 743.56 1,503 605.84 Forfeited — — (104 ) 668.65 Expired — — (530 ) 367.70 Balance – End of the period 869 743.56 869 743.56 Mr. Ernst did not stand for re-election at the Company’s May 8, 2019 annual and special meeting of shareholders and at such time his 23,000 DSUs granted in May 2018 became exercisable. As of the date hereof, the underlying common shares have not been issued.

Operating Expenses

Operating Expenses	6 Months Ended
	Jun. 30, 2019
Analysis of income and expense [abstract]
Operating Expenses	12 Operating expenses The nature of the Company’s operating expenses from continuing operations include the following: Six months ended June 30, 2019 2018 $ $ Key management personnel: Salaries and short-term employee benefits 594 1,229 Consultant fees 118 — Share-based compensation costs 681 39 Post-employment benefits 18 23 1,411 1,291 Other employees: Salaries and short-term employee benefits 1,042 543 Share-based compensation costs 9 25 Post-employment benefits 158 25 Termination benefits — 331 1,209 814 Professional fees 1,474 150 Restructuring costs 773 — Consulting fees 76 — Insurance 446 38 Third-party R&D 307 4,796 Contracted sales force — 155 Travel 84 31 Marketing services 2 576 Laboratory supplies 28 303 Other goods and services 64 231 Leasing costs, net of sublease receipts of $58 (2018 - $62) 176 264 Impairment of right of use asset (note 4) 401 — Write-off of other current assets 197 — Depreciation and amortization 136 35 Operating foreign exchange losses 17 51 6,801 8,735

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	6 Months Ended
	Jun. 30, 2019
Statement of cash flows [abstract]
Supplemental Disclosure of Cash Flow Information	13 Supplemental disclosure of cash flow information Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables 133 (189 ) (196 ) (269 ) Inventory (191 ) (379 ) (496 ) (816 ) Prepaid expenses and other current assets (267 ) 20 (123 ) (151 ) Other non-current assets — 151 — 151 Payables and accrued liabilities 502 (1,040 ) 247 (864 ) Provision for restructuring costs — — — (1,352 ) Income taxes payable — (396 ) — 2,904 Employee future benefits (note 10) (108 ) 260 (217 ) 144 Lease liabilities (18 ) — (38 ) — Provisions and other non-current liabilities — (217 ) — (280 ) 51 (1,790 ) (823 ) (533 )

Capital Disclosures

Capital Disclosures	6 Months Ended
	Jun. 30, 2019
Summary Of Business And Basis Of Preparation
Capital Disclosures	14 Capital disclosures The Company’s objective in managing capital, consisting of shareholders’ equity, with cash and cash equivalents and restricted cash being its primary components, is to ensure sufficient liquidity to fund R&D costs, selling expenses, G&A expenses and working capital requirements (see note 1 – Going Concern). Over the past several years, the Company has raised capital via public equity offerings and issuances under various ATM sales programs as its primary source of liquidity. The policy on dividends is to retain cash to keep funds available to finance the activities required to advance the Company’s product development portfolio and to pursue appropriate commercial opportunities as they may arise. The Company is not subject to any capital requirements imposed by any regulators or by any other external source.

Financial Instruments and Finan

Financial Instruments and Financial Risk Management	6 Months Ended
	Jun. 30, 2019
Warrant Liability
Financial Instruments and Financial Risk Management	15 Financial instruments and financial risk management Financial assets (liabilities) as at June 30, 2019 and December 31, 2018 are presented below. June 30, 2019 Financial assets at amortized cost Financial Financial Total $ $ $ $ Cash and cash equivalents * 9,683 — — 9,683 Trade and other receivables 494 — — 494 Restricted cash 367 — — 367 Payables and accrued liabilities — — (3,200 ) (3,200 ) Provision for restructuring and other costs — — (1,404 ) (1,404 ) Warrant liability — (1,451 ) — (1,451 ) 10,544 (1,451 ) (4,604 ) 4,489 December 31, 2018 Financial assets at amortized cost Financial Financial Total $ $ $ $ Cash and cash equivalents * 14,512 — — 14,512 Trade and other receivables 245 — — 245 Restricted cash 418 — — 418 Payables and accrued liabilities — — (2,940 ) (2,940 ) Provision for restructuring and other costs — — (1,298 ) (1,298 ) Warrant liability — (3,634 ) — (3,634 ) 15,175 (3,634 ) (4,238 ) 7,303 Fair value IFRS 13, establishes a hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The input levels discussed in IFRS 13 are: Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than quoted prices included within Level 1 that are observable for an asset or liability, either directly (i.e. prices) or indirectly (i.e. derived from prices). Level 3 – Inputs for an asset or liability that are not based on observable market data (unobservable inputs). As discussed above in note 9 - Warrant liability, the Black-Scholes valuation methodology uses “Level 2” inputs in calculating fair value. The carrying values of the Company’s cash and cash equivalents, trade and other receivables, restricted cash, payables and accrued liabilities and provision for restructuring and other costs approximate their fair values due to their short-term maturities or to the prevailing interest rates of the related instruments, which are comparable to those of the market. Financial risk factors The following provides disclosures relating to the nature and extent of the Company’s exposure to risks arising from financial instruments, including credit risk, liquidity risk and market risk (share price risk) and how the Company manages those risks. (a) Credit risk Credit risk is the risk of an unexpected loss if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company regularly monitors credit risk exposure and takes steps to mitigate the likelihood of this exposure resulting in losses. The Company’s exposure to credit risk currently relates to the financial assets at amortized cost in the table above. The Company holds its available cash in amounts that are readily convertible to known amounts of cash and deposits its cash balances with financial institutions that have an investment grade rating of at least “P-2” or the equivalent. This information is supplied by independent rating agencies where available and, if not available, the Company uses publicly available financial information to ensure that it invests its cash in creditworthy and reputable financial institutions. Once there are indicators that there is no reasonable expectation of recovery, such financial assets are written off but are still subject to enforcement activity. As at June 30, 2019, trade accounts receivable for an amount of approximately $272 were with three counterparties of which $55 was past due and impaired and fully provided for (December 31, 2018 - $197 with four counterparties and $55 past due and impaired and fully provided for). The licensee is obligated to pay its quarterly royalties, 60 days after quarter-end. Generally, the Company does not require collateral or other security from customers for trade accounts receivable; however, credit is extended following an evaluation of creditworthiness. In addition, the Company performs ongoing credit reviews of all of its customers and establishes an allowance for doubtful accounts. On this basis, as at June 30, 2019, the Company has provided for all outstanding and unpaid amounts relating to its operations before its licensing of Macrilen TM (macimorelin). The licensee has paid all amounts owing within 90 days of invoicing. The maximum exposure to credit risk approximates the amount recognized in the Company’s consolidated statement of financial position. (b) Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. As indicated in note 14 - Capital risk management, the Company manages this risk through the management of its capital structure. It also manages liquidity risk by continuously monitoring actual and projected cash flows as further discussed in note 1 – Going Concern. The Board of Directors reviews and approves the Company’s operating and capital budgets, as well as any material transactions occurring outside of the ordinary course of business. The Company has adopted an investment policy in respect of the safety and preservation of its capital to ensure the Company’s liquidity needs are met. The instruments are selected with regard to the expected timing of expenditures and prevailing interest rates. (c) Market risk Share price risk The change in fair value of the Company’s warrant liability, which is measured at FVTPL, results from the periodic “mark-to-market” revaluation, via the application of option pricing models, of currently outstanding share purchase warrants. These valuation models are impacted, among other inputs, by the market price of the Company’s common shares. As a result, the change in fair value of the warrant liability, which is reported in the consolidated statements of comprehensive loss, has been and may continue in future periods to be materially affected most notably by changes in the Company’s common share closing price, which on the NASDAQ ranged from $2.04 to $5.43 during the six-months ended June 30, 2019. If variations in the market price of our common shares of -30% and +30% were to occur, the impact on the Company’s net loss related to the warrant liability held at June 30, 2019 would be as follows: Carrying amount -30% +30% $ $ $ Warrant liability 1,451 1,122 (839 ) Total impact on net loss – decrease /(increase) 1,122 (839 ) (d) Foreign exchange risk Entities using the Euro as their functional currency The Company is exposed to foreign exchange risk due to its investments in foreign operations whose functional currency is the Euro. As at June 30, 2019, if the US dollar had increased or decreased by 10% against the Euro, with all variables held constant, net income for the six-month period ended June 30, 2019 would have been lower or higher by approximately $546 (2018 - $1,180).

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2019
Segment Information
Segment Information	16 Segment information The Company operates in a single operating segment, being the biopharmaceutical segment.

Net (Loss) Income Per Share

Net (Loss) Income Per Share	6 Months Ended
	Jun. 30, 2019
Earnings per share [abstract]
Net (Loss) Income Per Share	17 Net (loss) income per share The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 $ $ $ $ Net (loss) income 206 (2,602 ) (4,705 ) 11,822 Basic weighted average number of shares outstanding 16,622,415 16,440,760 16,532,090 16,440,760 Net (loss) income per share (basic) 0.01 (0.16 ) (0.28 ) 0.72 Dilutive effect of share purchase warrants — — — 48,604 Diluted weighted average number of shares outstanding 17,260,016 16,440,760 16,532,090 16,489,364 Net income (loss) per share (diluted) 0.01 (0.16 ) (0.28 ) 0.70 Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options 161,021 975,196 641,021 975,196 Deferred stock units 150,000 161,000 288,000 161,000 Warrants (number of equivalent shares) 3,276,000 3,417,840 3,296,008 3,301,996 Net (loss) income per share is calculated by dividing net (loss) income by the weighted average number of shares outstanding during the relevant period. Diluted weighted average number of shares reflects the dilutive effect of equity instruments, such as any “in the money” stock options and share purchase warrants. In periods with reported net losses, all stock options and share purchase warrants are deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal, and thus “in the money” stock options and share purchase warrants have not been included in the computation of net loss per share because to do so would be anti-dilutive.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies
Commitments and Contingencies	18 Commitments and contingencies Service and manufacturing $ Less than 1 year 2,528 1 - 3 years 13 4 - 5 years 13 More than 5 years 24 Total 2,578 Contingencies In the normal course of operations, the Company may become involved in various claims and legal proceedings related to, for example, contract terminations and employee-related and other matters. Securities class action lawsuit The Company’s securities class action lawsuit pending in the U.S. District Court for the District of New Jersey, brought on behalf of shareholders of the Company alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between August 30, 2011 and November 6, 2014 regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company’s New Drug Application for the product by the FDA. In February 2018, the U.S. court granted a motion for class certification in the case, and on May 30, 2019 the U.S Third Circuit Court of Appeals dismissed an appeal of that certification motion that had been brought by the Company. The Company considers the claims that have been asserted in the lawsuit to be without merit and is vigorously defending against them. The Company cannot, however, predict at this time the outcome or potential losses, if any, with respect to this lawsuit. The Company continues to believe that substantially all of the costs for its defense and indemnity will be borne by the insurers who provide directors’ and officers’ liability insurance to the Company, subject to policy limits. Other lawsuits On December 21, 2018, the Company settled a dispute with its former President and Chief Executive Officer and with its former Senior Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary with the Company agreeing to make a payment in the amount of $775. On November 5, 2018, the Company settled a dispute with Cogas Consulting, LLC with the Company agreeing to make a payment of $625.

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure of initial application of standards or interpretations [abstract]
Schedule of Operating Lease Liabilities	2019 Operating lease commitments disclosed as at December 31, 2018 1,620 Discounted using the lessee’s incremental borrowing rate of at the date of initial application: Lease liability recognized as at January 1, 2019 1,522 Current lease liabilities 629 Non-current lease liabilities 893 During the six-month period ended June 30, 2019 Cash lease payments made 348 Interest paid as charged to comprehensive profit and loss as other finance income 38 Payment against lease liabilities 310 Foreign exchange 7 Lease liability recognized as at June 30, 2019 1,205 Current lease liabilities 635 Non-current lease liabilities 570
Schedule of Maturity of Operating Lease Liabilities	The Company’s lease liabilities come due, as at June 30, 2019, as follows: $ Less than 1 year 635 1 - 3 years 560 4 - 5 years 10 More than 5 years — Total 1,205
Schedule of Right of Use Assets	Building Cars and equipment Total $ $ $ Cost At January 1, 2019 735 124 859 Additions — 26 26 Disposals — (25 ) (25 ) Impact of foreign exchange rate changes (4 ) (5 ) (9 ) At June 30, 2019 731 120 851 Building Cars and equipment Total $ $ $ Accumulated Amortization At January 1, 2019 — — — Disposals — (3 ) (3 ) Amortization 87 30 117 Impairment 401 — 401 Impact of foreign exchange rate changes (2 ) (2 ) (4 ) At June 30, 2019 486 25 511 Building Cars and equipment Total $ $ $ Carrying amount At June 30, 2019 245 95 340

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	6 Months Ended
	Jun. 30, 2019
Trade and other receivables [abstract]
Schedule of Trade and Other Receivables	June 30, 2019 December 31, 2018 $ $ Trade accounts receivable (net of allowance for doubtful accounts of $55 (December 31, 2018 - $55) 217 142 Value added tax 247 49 Other 30 103 494 294

Payables and Accrued Liabilit_2

Payables and Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2019
Subclassifications of assets, liabilities and equities [abstract]
Schedule of Payables and Accrued Liabilities	June 30, 2019 December 31, 2018 $ $ Trade accounts payable 1,197 1,282 Accrued research and development costs — 26 Salaries, employment taxes and benefits 258 183 Financing of insurance premiums (a) 210 738 Other accrued liabilities 1,535 737 3,200 2,966 (a) Represents financing of the Company’s 2019 insurance premiums, carrying interest at 6.5% and repayable in eight equal monthly installments commencing January 31, 2019.

Provision for Restructuring C_2

Provision for Restructuring Costs (Tables)	6 Months Ended
	Jun. 30, 2019
Subclassifications of assets, liabilities and equities [abstract]
Schedule of Provision for Restructuring and Other Costs	The changes in the Company’s provision for restructuring and other costs can be summarized as follows: Cetrotide(R) onerous contracts German Restructuring: onerous lease German Restructuring: severance Total $ $ $ $ Balance – January 1, 2019 547 663 88 1,298 Adoption of IFRS 16 (note 4) — (663 ) — (663 ) Utilization of provision (59 ) — — (59 ) Change in provision 59 — 773 832 Impact of foreign exchange rate changes (2 ) — (2 ) (4 ) Balance – June 30, 2019 545 — 859 1,404 Less current portion (145 ) — (859 ) (1,004 ) Non-current portion 400 — — 400

Warrant Liability (Tables)

Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2019
Warrant Liability
Schedule of Changes in Warrant Liability	The change in the Company’s warrant liability can be summarized as follows: Six months ended June 30, 2019 $ Balance – January 1, 2019 3,634 Exercise of warrants (318 ) Change in fair value of warrant liability (1,865 ) Balance – June 30, 2019 1,451 Current portion of warrant liability 447 Long-term portion of warrant liability 1,004
Summary of Share Purchase Warrant Activity	A summary of the activity related to the Company’s share purchase warrants that are classified as a liability is provided below. Six months ended June 30, 2019 Year ended December 31, 2018 Number Weighted average exercise price Number Weighted average exercise price $ $ Balance – Beginning of period 3,391,844 6.23 3,417,840 7.59 Exercised (87,700 ) 1.07 — — Expired — — (25,996 ) 185.00 Balance – End of period 3,304,144 6.36 3,391,844 6.23
Summary of Share Purchase Warrants Outstanding and Exercisable	The table presented below shows the inputs and assumptions applied to the Black-Scholes option pricing model in order to determine the fair value of all warrants outstanding as at June 30, 2019. The Black-Scholes option pricing model uses “Level 2” inputs, as defined by IFRS 13, Fair value measurement Number of equivalent shares Market value per share price Weighted average exercise price Risk-free annual interest rate Expected volatility Expected life (years) Expected dividend yield ($) ($) (a) (b) (c) (d) March 2015 Series A Warrants (e) 28,144 2.95 1.07 1.91 % 100.09 % 0.70 0.00 % December 2015 Warrants 2,331,000 2.95 7.10 1.83 % 80.62 % 1.46 0.00 % November 2016 Warrants (f) 945,000 2.95 4.70 1.91 % 92.73 % 0.84 0.00 % (a) Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants. (b) Based on the historical volatility of the Company’s stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations. (c) Based upon time to expiry from the reporting period date. (d) The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future. (e) For the March 2015 Series A Warrants, the inputs and assumptions applied to the Black-Scholes option pricing model have been further adjusted to take into consideration the value attributed to certain anti-dilution provisions. Specifically, the weighted average exercise price is subject to adjustment (see note 11 - Share and other capital). (f) For the November 2016 Warrants, the Company reduced the fair value of these warrants to take into consideration the fair value of the $10.00 call option, which was also calculated using the Black-Scholes pricing model.

Employee Future Benefits (Table

Employee Future Benefits (Tables)	6 Months Ended
	Jun. 30, 2019
Employee Future Benefits
Disclosure of Net Defined Benefit Liability (Asset)	The change in the Company’s accrued benefit obligations is summarized as follows: Six months ended June 30, 2019 Year ended December 31, 2018 Pension benefit plans Other benefit plans Total Total $ $ $ $ Balances – Beginning of the period 13,100 105 13,205 14,229 Current service cost 21 3 24 72 Interest cost 111 1 112 225 Actuarial loss (gain) arising from changes in financial assumptions 1,491 — 1,491 (174 ) Benefits paid (217 ) — (217 ) (494 ) Impact of foreign exchange rate changes (53 ) (1 ) (54 ) (653 ) Balances – End of the period 14,453 108 14,561 13,205 Amounts recognized: In net loss (132 ) (4 ) (136 ) (316 ) In other comprehensive loss 1,491 — 1,491 846

Share and Other Capital (Tables

Share and Other Capital (Tables)	6 Months Ended
	Jun. 30, 2019
Share And Other Capital
Disclosure of Change in Stock Options Issued	The following tables summarizes the activity under the LTIP and the Stock Option Plan: Six months ended Year ended June 30, 2019 December 31, 2018 US dollar-denominated stock options and DSU Number Weighted average exercise price Number Weighted average exercise price Balance – Beginning of the period 888,816 3.66 712,415 4.66 Granted 150,000 3.15 426,000 1.74 Exercised (110,850 ) 2.35 — — Forfeited — — (249,599 ) 3.23 Balance – End of period 927,966 3.76 888,816 3.66 Six months ended Year ended June 30, 2019 December 31, 2018 Canadian dollar-denominated options Number Weighted average exercise price Number Weighted average exercise price Balance – Beginning of the period 869 743.56 1,503 605.84 Forfeited — — (104 ) 668.65 Expired — — (530 ) 367.70 Balance – End of the period 869 743.56 869 743.56

Operating Expenses (Tables)

Operating Expenses (Tables)	6 Months Ended
	Jun. 30, 2019
Analysis of income and expense [abstract]
Schedule of Operating Expenses	The nature of the Company’s operating expenses from continuing operations include the following: Six months ended June 30, 2019 2018 $ $ Key management personnel: Salaries and short-term employee benefits 594 1,229 Consultant fees 118 — Share-based compensation costs 681 39 Post-employment benefits 18 23 1,411 1,291 Other employees: Salaries and short-term employee benefits 1,042 543 Share-based compensation costs 9 25 Post-employment benefits 158 25 Termination benefits — 331 1,209 814 Professional fees 1,474 150 Restructuring costs 773 — Consulting fees 76 — Insurance 446 38 Third-party R&D 307 4,796 Contracted sales force — 155 Travel 84 31 Marketing services 2 576 Laboratory supplies 28 303 Other goods and services 64 231 Leasing costs, net of sublease receipts of $58 (2018 - $62) 176 264 Impairment of right of use asset (note 4) 401 — Write-off of other current assets 197 — Depreciation and amortization 136 35 Operating foreign exchange losses 17 51 6,801 8,735

Supplemental Disclosure of Ca_2

Supplemental Disclosure of Cash Flow Information (Tables)	6 Months Ended
	Jun. 30, 2019
Statement of cash flows [abstract]
Disclosure of Changes in Operating Assets and Liabilities	Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 $ $ $ $ Changes in operating assets and liabilities: Trade and other receivables 133 (189 ) (196 ) (269 ) Inventory (191 ) (379 ) (496 ) (816 ) Prepaid expenses and other current assets (267 ) 20 (123 ) (151 ) Other non-current assets — 151 — 151 Payables and accrued liabilities 502 (1,040 ) 247 (864 ) Provision for restructuring costs — — — (1,352 ) Income taxes payable — (396 ) — 2,904 Employee future benefits (note 10) (108 ) 260 (217 ) 144 Lease liabilities (18 ) — (38 ) — Provisions and other non-current liabilities — (217 ) — (280 ) 51 (1,790 ) (823 ) (533 )

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management (Tables)	6 Months Ended
	Jun. 30, 2019
Warrant Liability
Disclosure of Fair Value Measurement of Assets	Financial assets (liabilities) as at June 30, 2019 and December 31, 2018 are presented below. June 30, 2019 Financial assets at amortized cost Financial Financial Total $ $ $ $ Cash and cash equivalents * 9,683 — — 9,683 Trade and other receivables 494 — — 494 Restricted cash 367 — — 367 Payables and accrued liabilities — — (3,200 ) (3,200 ) Provision for restructuring and other costs — — (1,404 ) (1,404 ) Warrant liability — (1,451 ) — (1,451 ) 10,544 (1,451 ) (4,604 ) 4,489 December 31, 2018 Financial assets at amortized cost Financial Financial Total $ $ $ $ Cash and cash equivalents * 14,512 — — 14,512 Trade and other receivables 245 — — 245 Restricted cash 418 — — 418 Payables and accrued liabilities — — (2,940 ) (2,940 ) Provision for restructuring and other costs — — (1,298 ) (1,298 ) Warrant liability — (3,634 ) — (3,634 ) 15,175 (3,634 ) (4,238 ) 7,303
Disclosure of Nature and Extent of Risks Arising from Financial Instruments	If variations in the market price of our common shares of -30% and +30% were to occur, the impact on the Company’s net loss related to the warrant liability held at June 30, 2019 would be as follows: Carrying amount -30% +30% $ $ $ Warrant liability 1,451 1,122 (839 ) Total impact on net loss – decrease /(increase) 1,122 (839 )

Net (Loss) Income Per Share (Ta

Net (Loss) Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings per share [abstract]
Summary of Pertinent Data Relating to Computation of Basic and Diluted Net (Loss) Income Per Share	The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. Three months ended June 30, Six months ended June 30, 2019 2018 2019 2018 $ $ $ $ Net (loss) income 206 (2,602 ) (4,705 ) 11,822 Basic weighted average number of shares outstanding 16,622,415 16,440,760 16,532,090 16,440,760 Net (loss) income per share (basic) 0.01 (0.16 ) (0.28 ) 0.72 Dilutive effect of share purchase warrants — — — 48,604 Diluted weighted average number of shares outstanding 17,260,016 16,440,760 16,532,090 16,489,364 Net income (loss) per share (diluted) 0.01 (0.16 ) (0.28 ) 0.70 Items excluded from the calculation of diluted net loss per share because the exercise price was greater than the average market price of the common shares or due to their anti-dilutive effect Stock options 161,021 975,196 641,021 975,196 Deferred stock units 150,000 161,000 288,000 161,000 Warrants (number of equivalent shares) 3,276,000 3,417,840 3,296,008 3,301,996

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2019
Commitments And Contingencies
Schedule of Expected Future Minimum Lease Payments	Service and manufacturing $ Less than 1 year 2,528 1 - 3 years 13 4 - 5 years 13 More than 5 years 24 Total 2,578

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Statement Line Items [Line Items]
Accumulated deficit	$ (315,977,000)		$ (315,977,000)		$ (309,781,000)
Net loss	206,000	$ (2,602,000)	(4,705,000)	$ 11,822,000
Net cash (used in) provided by operating activities	(2,170,000)	(4,777,000)	(5,176,000)	11,940,000
Licensing revenue	18,000	$ 89,000	36,000	24,657,000
License and Assignment Agreement [Member] | Macrilen [Member]
Statement Line Items [Line Items]
Net loss			(4,700,000)
Net cash (used in) provided by operating activities			(5,176,000)
Licensing revenue			21,000
Cash	$ 9,683,000		$ 9,683,000
Novo Nordisk A/S [Member]
Statement Line Items [Line Items]
Percentage of cost sharing			70.00%

Recent Accounting Pronounceme_3

Recent Accounting Pronouncements (Details Narrative) - USD ($) $ in Thousands	Jan. 02, 2019	Jun. 30, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Weighted average incremental borrowing rate	5.45%
Lease liabilities		$ 1,205	$ 1,620
Operating lease expiration description		The Company leases various office and lab premises (building), cars and equipment. The building lease was originally for 10 years with one five-year extension, such extension is ending on April 30, 2021. Car lease contracts are typically made for fixed periods of three to four years while the equipment lease is for five years ending April 30, 2020.
Buildings [Member]
Statement Line Items [Line Items]
Operating lease arrangements period		10 years
Equipment [Member]
Statement Line Items [Line Items]
Operating lease arrangements period		5 years
IFRS 16 Leases [Member]
Statement Line Items [Line Items]
Impairment of right of use assets		$ 401
Right of use assets	$ 859
Lease liabilities	1,522
IFRS 16 Leases [Member] | Onerous Lease Provision Building Asset [Member]
Statement Line Items [Line Items]
Impairment of right of use assets		337
IFRS 16 Leases [Member] | Restructuring of German operations on underutlized office and lab space [Member]
Statement Line Items [Line Items]
Impairment of right of use assets		$ 64
IFRS 16 Leases [Member] | Onerous Lease Contracts [Member]
Statement Line Items [Line Items]
Impairment of right of use assets	$ 663
-30% Bottom of range [Member] | Cars and Equipment [Member]
Statement Line Items [Line Items]
Operating lease arrangements period		3 years
+30% Top of range [member] | Cars and Equipment [Member]
Statement Line Items [Line Items]
Operating lease arrangements period		4 years
Buildings [Member]
Statement Line Items [Line Items]
Incremental annual borrowing rate to lease liabilities	5.50%
Buildings [Member] | IFRS 16 Leases [Member]
Statement Line Items [Line Items]
Impairment of right of use assets		$ 401
Car [Member] | -30% Bottom of range [Member]
Statement Line Items [Line Items]
Incremental annual borrowing rate to lease liabilities	4.84%
Car [Member] | +30% Top of range [member]
Statement Line Items [Line Items]
Incremental annual borrowing rate to lease liabilities	5.32%
Equipment [Member]
Statement Line Items [Line Items]
Incremental annual borrowing rate to lease liabilities	3.88%

Recent Accounting Pronounceme_4

Recent Accounting Pronouncements - Schedule of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jan. 02, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Lease liability recognized	$ 1,205		$ 1,205			$ 1,620
Current lease liabilities	635		635
Non-current lease liabilities	570		570
Cash lease payments made			348
Interest paid as charged to comprehensive profit and loss as other finance income			38
Payment against lease liabilities	$ 159		310
Foreign exchange			$ 7
IFRS 16 Leases [Member]
Statement Line Items [Line Items]
Lease liability recognized					$ 1,522
Current lease liabilities					629
Non-current lease liabilities					$ 893

Recent Accounting Pronounceme_5

Recent Accounting Pronouncements - Schedule of Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Lease liability	$ 1,205	$ 1,620
Less than 1 year [Member]
Statement Line Items [Line Items]
Lease liability	635
1 - 3 years [Member]
Statement Line Items [Line Items]
Lease liability	560
4 - 5 years [Member]
Statement Line Items [Line Items]
Lease liability	10
More than 5 years [Member]
Statement Line Items [Line Items]
Lease liability

Recent Accounting Pronounceme_6

Recent Accounting Pronouncements - Schedule of Right of Use Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Right of use assets, at cost, begining
Impact of foreign exchange rate changes	$ 341	$ 175	293	$ 215
Right of use assets, at cost, ending	340		340
IFRS 16 Leases [Member]
Statement Line Items [Line Items]
Right of use assets, at cost, begining			859
Additions			26
Disposals			(25)
Impact of foreign exchange rate changes			(9)
Right of use assets, at cost, ending	851		851
Accumulated amortization, Begining
Disposals			(3)
Amortization			117
Impairment			401
Impact of foreign exchange rate changes			(4)
Accumulated amortization, ending	511		511
Right of use assets, carrying amount	340		340
IFRS 16 Leases [Member] | Buildings [Member]
Statement Line Items [Line Items]
Right of use assets, at cost, begining			735
Additions
Disposals
Impact of foreign exchange rate changes			(4)
Right of use assets, at cost, ending	731		731
Accumulated amortization, Begining
Disposals
Amortization			87
Impairment			401
Impact of foreign exchange rate changes			(2)
Accumulated amortization, ending	486		486
Right of use assets, carrying amount	245		245
IFRS 16 Leases [Member] | Cars and Equipment [Member]
Statement Line Items [Line Items]
Right of use assets, at cost, begining			124
Additions			26
Disposals			(25)
Impact of foreign exchange rate changes			(5)
Right of use assets, at cost, ending	120		120
Accumulated amortization, Begining
Disposals			(3)
Amortization			30
Impairment
Impact of foreign exchange rate changes			(2)
Accumulated amortization, ending	25		25
Right of use assets, carrying amount	$ 95		$ 95

Licensing Arrangement (Details

Licensing Arrangement (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Licensing revenue	$ 18	$ 89	$ 36	$ 24,657
PIP study costs			621
Supply chain costs			839
License and Assignment Agreement [Member] | Macrilen [Member]
Statement Line Items [Line Items]
Licensing revenue			$ 21
Novo Nordisk A/S [Member]
Statement Line Items [Line Items]
Percentage of cost sharing			70.00%

Trade and Other Receivables (De

Trade and Other Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Trade and other receivables [abstract]
Trade accounts receivable (net of allowance for doubtful accounts of $55 (December 31, 2018 - $55)	$ 217	$ 142
Value added tax	247	49
Other	30	103
Trade and other receivables	$ 494	$ 294

Trade and Other Receivables (_2

Trade and Other Receivables (Details) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Trade and other receivables [abstract]
Trade accounts receivable net of allowance for doubtful accounts	$ 55	$ 55

Payables and Accrued Liabilit_3

Payables and Accrued Liabilities (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Trade accounts payable		$ 1,197	$ 1,282
Accrued research and development costs			26
Salaries, employment taxes and benefits		258	183
Financing of insurance premiums	[1]	210	738
Other accrued liabilities		1,535	737
Payables and accrued liabilities		$ 3,200	$ 2,966
[1]	Represents financing of the Company's 2019 insurance premiums, carrying interest at 6.5% and repayable in eight equal monthly installments commencing January 31, 2019.

Payables and Accrued Liabilit_4

Payables and Accrued Liabilities (Details) (Parenthetical)	Jan. 31, 2019Installment
Subclassifications of assets, liabilities and equities [abstract]
Insurance premium, interest rate	6.50%
Insurance premium, number of monthly payments	8

Provision for Restructuring C_3

Provision for Restructuring Costs (Details Narrative) - 2017 German Restructuring [Member] $ in Thousands	Jun. 06, 2019USD ($)Employee
Statement Line Items [Line Items]
Number of employees | Employee	8
Severance cost | $	$ 773

Provision for Restructuring C_4

Provision for Restructuring Costs - Schedule of Provision for Restructuring and Other Costs (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Beginning balance	$ 1,298
Adoption of IFRS 16 (note 4)	(663)
Utilization of provision	(59)
Change in provision	832
Impact of foreign exchange rate changes	(4)
Ending balance	1,404
Less current portion	(1,004)	$ (887)
Non-current portion	400
Cetrotide(R) Onerous Contracts [Member]
Statement Line Items [Line Items]
Beginning balance	547
Adoption of IFRS 16 (note 4)
Utilization of provision	(59)
Change in provision	59
Impact of foreign exchange rate changes	(2)
Ending balance	545
Less current portion	(145)
Non-current portion	400
German Restructuring Onerous Lease [Member]
Statement Line Items [Line Items]
Beginning balance	663
Adoption of IFRS 16 (note 4)	(663)
Utilization of provision
Change in provision
Impact of foreign exchange rate changes
Ending balance
Less current portion
Non-current portion
German Restructuring Severance [Member]
Statement Line Items [Line Items]
Beginning balance	88
Adoption of IFRS 16 (note 4)
Utilization of provision
Change in provision	773
Impact of foreign exchange rate changes	(2)
Ending balance	859
Less current portion	(859)
Non-current portion

Warrant Liability - Schedule of

Warrant Liability - Schedule of Changes in Warrant Liability (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Current portion of warrant liability	$ 447
Warrant Liability [Member]
Statement Line Items [Line Items]
Balance – Beginning of the year	3,634
Exercise of warrants	(318)
Change in fair value of warrant liability	(1,865)
Balance - End of the year	1,451
Current portion of warrant liability	447
Long-term portion of warrant liability	$ 1,004

Warrant Liability - Summary of

Warrant Liability - Summary of Share Purchase Warrant Activity (Details) - Warrant Liability [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Warrants outstanding, beginning	3,391,844	3,417,840
Warrants exercised	(87,700)
Warrants expired		(25,996)
Warrants outstanding, end of period	3,304,144	3,391,844
Weighted average exercise price, beginning of period	$ 6.23	$ 7.59
Weighted average exercise price, exercised	1.07
Weighted average exercise price, expired		185
Weighted average exercise price, end of period	$ 6.36	$ 6.23

Warrant Liability - Summary o_2

Warrant Liability - Summary of Share Purchase Warrants Outstanding and Exercisable (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
March 2015 Series A Warrants [Member]
Statement Line Items [Line Items]
Number of equivalent shares | shares	28,144	[1]
Market value per share price	$ 2.95	[1]
Weighted average exercise price	$ 1.07	[1]
Risk-free annual interest rate	1.91%	[1],[2]
Expected volatility	100.09%	[1],[3]
Expected life	8 months 12 days	[1],[4]
Expected dividend yield	0.00%	[1],[5]
December 2015 Warrants [Member]
Statement Line Items [Line Items]
Number of equivalent shares | shares	2,331,000
Market value per share price	$ 2.95
Weighted average exercise price	$ 7.10
Risk-free annual interest rate	1.83%	[2]
Expected volatility	80.62%	[3]
Expected life	1 year 5 months 16 days	[4]
Expected dividend yield	0.00%	[5]
November 2016 Warrants [Member]
Statement Line Items [Line Items]
Number of equivalent shares | shares	945,000	[6]
Market value per share price	$ 2.95	[6]
Weighted average exercise price	$ 4.70	[6]
Risk-free annual interest rate	1.91%	[2],[6]
Expected volatility	92.73%	[3],[6]
Expected life	10 months 3 days	[4],[6]
Expected dividend yield	0.00%	[5],[6]
[1]	For the March 2015 Series A Warrants, the inputs and assumptions applied to the Black-Scholes option pricing model have been further adjusted to take into consideration the value attributed to certain anti-dilution provisions. Specifically, the weighted average exercise price is subject to adjustment (see note 11 - Share and other capital).
[2]	Based on United States Treasury Government Bond interest rates with a term that is consistent with the expected life of the warrants.
[3]	Based on the historical volatility of the Company's stock price over the most recent period consistent with the expected life of the warrants, as well as on future expectations.
[4]	Based upon time to expiry from the reporting period date.
[5]	The Company has not paid dividends and it does not intend to pay dividends in the foreseeable future.
[6]	For the November 2016 Warrants, the Company reduced the fair value of these warrants to take into consideration the fair value of the $10.00 call option, which was also calculated using the Black-Scholes pricing model.

Warrant Liability - Summary o_3

Warrant Liability - Summary of Share Purchase Warrants Outstanding and Exercisable (Details) (Parenthetical)	6 Months Ended
	Jun. 30, 2019$ / shares
Warrant Liability
Other equity, call option price	$ 10

Employee Future Benefits (Detai

Employee Future Benefits (Details Narrative) - Pension Benefit Plans [Member]	Jun. 30, 2019	Mar. 31, 2019
-30% Bottom of range [Member]
Disclosure of defined benefit plans [line items]
Discount rate	1.40%	1.90%
+30% Top of range [member]
Disclosure of defined benefit plans [line items]
Discount rate	1.10%	1.40%

Employee Future Benefits - Disc

Employee Future Benefits - Disclosure of Net Defined Benefit Liability (Asset) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Disclosure of net defined benefit liability (asset) [line items]
Balances – Beginning of the year	$ 13,205	$ 14,229
Current service cost	24	72
Interest cost	112	225
Actuarial loss (gain) arising from changes in financial assumptions	1,491	(174)
Benefits paid	(217)	(494)
Impact of foreign exchange rate changes	(54)	(653)
Balances – End of the year	14,561	13,205
Amounts recognized in net loss	(136)	(316)
Amounts recognized in other comprehensive loss	1,491	846
Pension Benefit Plans [Member] | Unfunded Plan One [Member]
Disclosure of net defined benefit liability (asset) [line items]
Balances – Beginning of the year	13,100
Current service cost	21
Interest cost	111
Actuarial loss (gain) arising from changes in financial assumptions	1,491
Benefits paid	(217)
Impact of foreign exchange rate changes	(53)
Balances – End of the year	14,453	13,100
Amounts recognized in net loss	(132)
Amounts recognized in other comprehensive loss	1,491
Other Benefit Plans [Member] | Unfunded Plan One [Member]
Disclosure of net defined benefit liability (asset) [line items]
Balances – Beginning of the year	105
Current service cost	3
Interest cost	1
Actuarial loss (gain) arising from changes in financial assumptions
Benefits paid
Impact of foreign exchange rate changes	(1)
Balances – End of the year	108	$ 105
Amounts recognized in net loss	(4)
Amounts recognized in other comprehensive loss

Share and Other Capital (Detail

Share and Other Capital (Details Narrative)	May 08, 2019Employee
Share And Other Capital
DSU's granted and exercisable	23,000

Share and Other Capital - Discl

Share and Other Capital - Disclosure of Change in Stock Options Issued (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2019Employee$ / shares	Jun. 30, 2019Employee$ / shares	Dec. 31, 2018Employee$ / shares	Dec. 31, 2018Employee$ / shares
Employee Stock Option USD [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance - Beginning of the year, Number (in shares)	888,816	888,816	712,415	712,415
Granted, Number (in shares)	150,000	150,000	426,000	426,000
Exercised, Number (in shares)	(110,850)	(110,850)
Forfeited, Number (in shares)			(249,599)	(249,599)
Balance - End of period, Number (in shares)	927,966	927,966	888,816	888,816
Balance - Beginning of the year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	$ 3.66		$ 4.66
Granted, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	3.15		1.74
Exercised, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	2.35
Forfeited, Weighted average exercise price (in US and CAN dollars per share) | $ / shares			3.23
Balance - End of period, Weighted average exercise price (in US and CAN dollars per share) | $ / shares	$ 3.76		$ 3.66
Employee Stock Option CAD [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance - Beginning of the year, Number (in shares)	869	869	1,503	1,503
Forfeited, Number (in shares)			(104)	(104)
Expired, Number (in shares)			(530)	(530)
Balance - End of period, Number (in shares)	869	869	869	869
Balance - Beginning of the year, Weighted average exercise price (in US and CAN dollars per share) | $ / shares		$ 743.56		$ 605.84
Forfeited, Weighted average exercise price (in US and CAN dollars per share) | (per share)				668.65
Expired, Weighted average exercise price (in US and CAN dollars per share) | (per share)				367.70
Balance - End of period, Weighted average exercise price (in US and CAN dollars per share) | $ / shares		$ 743.56		$ 743.56

Operating Expenses - Disclosure

Operating Expenses - Disclosure of Operating Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement Line Items [Line Items]
Restructuring costs	$ 773		$ 773
Impairment of right of use asset (note 4)	64		401
Total operating expenses	$ 3,826	$ 3,475	6,801	8,735
Unfunded Plan One [Member] | Other Benefit Plans [Member]
Statement Line Items [Line Items]
Salaries and short-term employee benefits			594	1,229
Consultants fees			118
Share-based compensation costs			681	39
Post-employment benefits			18	23
Key management personnel compensation			1,411	1,291
Salaries and short-term employee benefits			1,042	543
Share-based compensation costs			9	25
Post-employment benefits			158	25
Termination benefits				331
Other employee compensation			1,209	814
Professional fees			1,474	150
Restructuring costs			773
Consulting fees			76
Insurance			446	38
Third-party R&D			307	4,796
Contracted sales force				155
Travel			84	31
Marketing services			2	576
Laboratory supplies			28	303
Other goods and services			64	231
Leasing costs, net of sublease receipts			176	264
Impairment of right of use asset (note 4)			401
Write-off of other current assets			197
Depreciation and amortization			136	35
Operating foreign exchange losses			17	51
Total operating expenses			$ 6,801	$ 8,735

Supplemental Disclosure of Ca_3

Supplemental Disclosure of Cash Flow Information - Disclosure of Changes in Operating Assets and Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement of cash flows [abstract]
Trade and other receivables	$ 133	$ (189)	$ (196)	$ (269)
Inventory	(191)	(379)	(496)	(816)
Prepaid expenses and other current assets	(267)	20	(123)	(151)
Other non-current assets		151		151
Payables and accrued liabilities	502	(1,040)	247	(864)
Provision for restructuring costs				(1,352)
Income taxes payable		(396)		2,904
Employee future benefits (note 10)	(108)	260	(217)	144
Lease liabilities	(18)		(38)
Provisions and other non-current liabilities		(217)		(280)
Increase (decrease) in operating assets and liabilities	$ 51	$ (1,790)	$ (823)	$ (533)

Financial Instruments and Fin_3

Financial Instruments and Financial Risk Management (Details Narrative) $ / shares in Units, $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2019USD ($)counterparty$ / shares	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)counterparty
Disclosure of nature and extent of risks arising from financial instruments [line items]
Foreign exchange risk, description	As at June 30, 2019, if the US dollar had increased or decreased by 10% against the Euro, with all variables held constant, net income for the six-month period ended June 30, 2019 would have been lower or higher by approximately $546 (2018 - $1,180).
Foreign exchange risk exposure	$ 546	$ 1,180
Trade and Other Current Receivables [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Trade receivables, number of counterparties | counterparty	3		4
Trade and Other Current Receivables [Member] | Credit risk [member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Trade accounts receivables	$ 272		$ 197
Trade and Other Current Receivables [Member] | Financial assets past due but not impaired [member] | Credit risk [member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Trade accounts receivables			$ 55
Trade and Warrant Liability [Member] | -30% Bottom of range [Member] | Equity Price Risk [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Common stock, share price | $ / shares	$ 2.04
Trade and Warrant Liability [Member] | +30% Top of range [member] | Equity Price Risk [Member]
Disclosure of nature and extent of risks arising from financial instruments [line items]
Common stock, share price | $ / shares	$ 5.43

Financial Instruments and Fin_4

Financial Instruments and Financial Risk Management - Disclosure of Fair Value Measurement of Assets (Details) - USD ($) $ in Thousands		Jun. 30, 2019	Dec. 31, 2018
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		$ 4,489	$ 7,303
Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(1,451)	(3,634)
Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(4,604)	(4,238)
Payables And Accrued Liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(3,200)	(2,940)
Provision For Restructuring And Other Costs [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(1,404)	(1,298)
Warrant Liability [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(1,451)	(3,634)
Payables And Accrued Liabilities [Member] | Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Payables And Accrued Liabilities [Member] | Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(3,200)	(2,940)
Provision For Restructuring And Other Costs [Member] | Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Provision For Restructuring And Other Costs [Member] | Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)			(1,298)
Warrant Liability [Member] | Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(1,451)	(3,634)
Warrant Liability [Member] | Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		(1,404)
Cash and Cash Equivalents [Member] | Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)	[1]
Cash and Cash Equivalents [Member] | Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)	[1]
Trade And Other Receivables [Member] | Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Trade And Other Receivables [Member] | Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Restricted Cash [Member] | Financial liabilities at fair value through profit or loss, category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Restricted Cash [Member] | Financial Liabilities At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Financial Assets At Amortised Cost Category [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		10,544	15,175
Financial Assets At Amortised Cost Category [Member] | Payables And Accrued Liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Financial Assets At Amortised Cost Category [Member] | Provision For Restructuring And Other Costs [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Financial Assets At Amortised Cost Category [Member] | Warrant Liability [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)
Financial Assets At Amortised Cost Category [Member] | Cash and Cash Equivalents [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)	[1]	9,683	14,512
Financial Assets At Amortised Cost Category [Member] | Trade And Other Receivables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		494	245
Financial Assets At Amortised Cost Category [Member] | Restricted Cash [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		367	418
Cash and Cash Equivalents [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)	[1]	9,683	14,512
Trade And Other Receivables [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		494	245
Restricted Cash [Member]
Disclosure of detailed information about financial instruments [line items]
Financial asset (liabilities)		$ 367	$ 418
[1]	As of June 30, 2019 and December 31, 2018, cash and cash equivalents consisted only of balances with banks.

Financial Instruments and Fin_5

Financial Instruments and Financial Risk Management - Disclosure of Nature and Extent of Risks Arising from Financial Instruments (Details) $ in Thousands	Jun. 30, 2019USD ($)
-30% Bottom of range [Member]
Disclosure of detailed information about financial instruments [line items]
Sensitivity analysis for types of market risk, reasonably possible change in risk variable, other relevant impact	$ 1,122
+30% Top of range [member]
Disclosure of detailed information about financial instruments [line items]
Sensitivity analysis for types of market risk, reasonably possible change in risk variable, other relevant impact	(839)
Warrant Liability [Member]
Disclosure of detailed information about financial instruments [line items]
Warrant liability	1,451
Warrant Liability [Member] | -30% Bottom of range [Member] | Market risk [Member]
Disclosure of detailed information about financial instruments [line items]
Sensitivity analysis for types of market risk, reasonably possible change in risk variable, other relevant impact	1,122
Warrant Liability [Member] | +30% Top of range [member] | Market risk [Member]
Disclosure of detailed information about financial instruments [line items]
Sensitivity analysis for types of market risk, reasonably possible change in risk variable, other relevant impact	$ (839)

Segment Information (Details Na

Segment Information (Details Narrative)	6 Months Ended
	Jun. 30, 2019Segment
Segment Information
Number of Operating Segments	1

Net (Loss) Income Per Share - D

Net (Loss) Income Per Share - Disclosure of Pertinent Data Relating to Computation of Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings per share [line items]
Net income (loss)	$ 206	$ (2,602)	$ (4,705)	$ 11,822
Basic weighted average number of shares outstanding (in shares)	16,622,415	16,440,760	16,532,090	16,440,760
Net (loss) income per share (basic)	$ 0.01	$ (0.16)	$ (0.28)	$ 0.72
Dilutive effect of share purchase warrants				48,604
Diluted weighted average number of shares outstanding (in shares)	17,260,016	16,440,760	16,532,090	16,489,364
Net income (loss) per share (diluted)	$ 0.01	$ (0.16)	$ (0.28)	$ 0.70
Stock Options [Member]
Earnings per share [line items]
Antidilutive securities excluded from computation of earnings per share (in shares)	161,021	975,196	641,021	975,196
Deferred Stock Units [Member]
Earnings per share [line items]
Antidilutive securities excluded from computation of earnings per share (in shares)	161,000	150,000	288,000	161,000
Stock Purchase Warrants [Member]
Earnings per share [line items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,417,840	3,276,000	3,296,008	3,301,996

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	Dec. 21, 2018	Nov. 05, 2018
Disclosure of contingent liabilities [line items]
Payments for legal settlements	$ 775
Cogas Consulting LLC [Member]
Disclosure of contingent liabilities [line items]
Payments for legal settlements		$ 625

Commitments and Contingencies -

Commitments and Contingencies - Disclosure of Expected Future Minimum Lease Payments (Details) $ in Thousands	Jun. 30, 2019USD ($)
Statement Line Items [Line Items]
Total	$ 2,578
Less Than 1 Year [Member]
Statement Line Items [Line Items]
Service and manufacturing	2,528
1 - 3 Years [Member]
Statement Line Items [Line Items]
Service and manufacturing	13
4 - 5 Years [Member]
Statement Line Items [Line Items]
Service and manufacturing	13
More than 5 Years [Member]
Statement Line Items [Line Items]
Service and manufacturing	$ 24